Hepatitis B Surface Antigen Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Hepatitis B Surface Antigen?

Hepatitis B surface antigen (HBsAg) is a protein found on the outer surface of the hepatitis B virus (HBV). It is the earliest detectable marker of hepatitis B infection, often appearing in the blood 1-10 weeks before symptoms develop and 2-6 weeks before liver enzymes become elevated.

HBsAg is the primary screening test for hepatitis B infection worldwide. Its presence in the blood indicates that the person is currently infected with HBV and is potentially infectious to others. The surface antigen is produced in large quantities during viral replication, far more than is needed to assemble complete viral particles, which is why it can be detected even when viral loads are relatively low.

The clinical significance of HBsAg depends on how long it remains detectable:

• Acute hepatitis B: HBsAg appears during the incubation period and typically clears within 6 months as the immune system resolves the infection. Clearance of HBsAg, followed by the development of anti-HBs (surface antibody), signals recovery and immunity.
• Chronic hepatitis B: If HBsAg remains detectable for more than 6 months, the infection is classified as chronic. Approximately 5% of adults infected with HBV develop chronic infection, compared with up to 90% of infants infected at birth.

In the UK, hepatitis B is a notifiable disease. Public Health England estimates that around 180,000 people in the UK are living with chronic hepatitis B, with many remaining undiagnosed. Early detection through HBsAg screening is critical for treatment, monitoring, and preventing transmission.

Why Is Hepatitis B Surface Antigen Tested?

HBsAg is the cornerstone of hepatitis B screening and is tested for multiple clinical reasons:

• Routine antenatal screening: All pregnant women in the UK are offered HBsAg testing as part of the NHS antenatal screening programme. Identifying HBsAg-positive mothers enables timely vaccination and immunoglobulin administration to newborns, preventing vertical transmission.
• Blood and organ donation screening: NHS Blood and Transplant tests all donations for HBsAg to prevent transfusion-transmitted hepatitis B.
• Diagnostic testing: If clinical features suggest acute hepatitis (jaundice, dark urine, fatigue, abdominal pain, elevated liver enzymes), HBsAg testing determines whether hepatitis B is the cause.
• At-risk population screening: NICE recommends HBsAg screening for individuals at increased risk, including people who inject drugs, men who have sex with men, people born in endemic countries, household and sexual contacts of known carriers, and prisoners.
• Pre-immunosuppression assessment: Before starting chemotherapy, biological therapies, or transplant-related immunosuppression, HBsAg testing identifies active infection that could flare dangerously under immune suppression.
• Occupational health: Healthcare workers and others in exposure-prone roles may be tested to assess infection status and inform workplace safety decisions.
• Treatment monitoring: In chronic hepatitis B, HBsAg quantification can help guide treatment decisions and assess response to antiviral therapy. HBsAg loss (seroconversion) is considered the optimal treatment endpoint.

Normal Ranges

HBsAg is reported as a qualitative result (reactive or non-reactive). Some laboratories also offer quantitative HBsAg measurement, which is useful for monitoring chronic infection.

Result	Interpretation
Non-reactive (Negative)	No hepatitis B surface antigen detected; not currently infected with HBV
Reactive (Positive)	Hepatitis B surface antigen detected; current HBV infection (acute or chronic)
Equivocal	Indeterminate result; confirmatory testing required (repeat or neutralisation assay)

For quantitative HBsAg measurement (used in chronic hepatitis B management):

Quantitative HBsAg (IU/mL)	Clinical Significance
> 1,000	High levels - typically indicates active viral replication
100 – 1,000	Moderate levels - may indicate immune control phase
< 100	Low levels - suggests good immune control or approaching seroconversion
Undetectable	HBsAg loss - functional cure if sustained

HBsAg results should always be interpreted alongside other hepatitis B markers (anti-HBs, anti-HBc, HBeAg, anti-HBe) and HBV DNA levels to fully characterise the infection stage and guide management.

What Do Positive Hepatitis B Surface Antigen Results Mean?

A positive HBsAg result confirms current hepatitis B infection. The clinical implications include:

• Acute hepatitis B infection: If this is a new finding, you may be in the acute phase of infection. Approximately 95% of immunocompetent adults will clear the virus spontaneously within 6 months. Symptoms range from none (subclinical) to jaundice, fatigue, nausea, and abdominal pain.
• Chronic hepatitis B infection: If HBsAg has been positive for more than 6 months, the infection is chronic. Chronic hepatitis B can progress through several phases (immune tolerant, immune active, inactive carrier, reactivation) with varying implications for liver damage and treatment.
• Infectivity: A person who is HBsAg-positive is potentially infectious to others through blood, sexual contact, and vertical (mother-to-child) transmission. The degree of infectivity depends on HBV DNA levels and HBeAg status.
• Risk of liver disease: Chronic HBsAg positivity carries long-term risks of cirrhosis (estimated 15-40% lifetime risk) and hepatocellular carcinoma (annual incidence 0.5-1% without cirrhosis, 2-5% with cirrhosis).
• Need for specialist referral: NICE recommends that all HBsAg-positive individuals are referred to hepatology or infectious disease services for comprehensive assessment, including HBV DNA quantification, liver function tests, HBeAg/anti-HBe status, and liver fibrosis assessment.
• Notification requirement: Acute hepatitis B is a notifiable disease in the UK. Your healthcare provider is legally required to report confirmed cases to Public Health England.
• Contact tracing: Household members, sexual partners, and others at risk of exposure should be identified, tested, and offered vaccination if not already immune.

What Do Negative Hepatitis B Surface Antigen Results Mean?

A negative HBsAg result is reassuring but requires context:

• No current infection: The most common interpretation - you are not currently infected with hepatitis B. This does not tell you whether you are immune (anti-HBs testing is needed for that).
• Resolved past infection: If you had hepatitis B in the past and cleared the virus, HBsAg will be negative. Anti-HBc (positive) and anti-HBs (positive) confirm resolved infection with natural immunity.
• Successful vaccination without infection: Vaccinated individuals who have never been infected will be HBsAg negative, anti-HBs positive, and anti-HBc negative.
• Window period: In rare cases, HBsAg may have been cleared from the blood but anti-HBs has not yet appeared. This "window period" can last days to weeks. Anti-HBc IgM is the diagnostic marker during this phase.
• Occult hepatitis B: In a small minority of cases, HBsAg may be undetectable despite low-level HBV DNA in the liver. This "occult hepatitis B" is identified through HBV DNA testing and is clinically significant in the context of immunosuppression, organ transplantation, and blood donation.
• Very early incubation period: If testing is performed during the earliest incubation period (first 1-3 weeks after exposure), HBsAg may not yet have reached detectable levels. Repeat testing is advisable if recent exposure is suspected.

How to Manage Your Hepatitis B Surface Antigen Status

Management depends entirely on your HBsAg result and overall hepatitis B profile:

If HBsAg Positive - Acute Infection

• Supportive care: Most acute infections resolve spontaneously. Rest, adequate hydration, and avoidance of alcohol and hepatotoxic medications are recommended.
• Monitoring: Regular blood tests (liver function, HBsAg, and HBV DNA) are needed to confirm resolution. If HBsAg does not clear within 6 months, the infection is reclassified as chronic.
• Prevent transmission: Practise safe sex (use barrier contraception), do not share razors, toothbrushes, or needles, and ensure close contacts are tested and vaccinated.

If HBsAg Positive - Chronic Infection

• Specialist management: NICE guideline NG165 recommends ongoing hepatology follow-up with regular monitoring of HBV DNA, liver function, and fibrosis assessment.
• Antiviral therapy: First-line treatments include tenofovir disoproxil (or tenofovir alafenamide) and entecavir. Treatment aims to suppress viral replication, reduce liver inflammation, prevent cirrhosis, and reduce hepatocellular carcinoma risk.
• Pegylated interferon alpha: A finite course (typically 48 weeks) may be offered to selected patients, particularly those with HBeAg-positive infection, with the goal of achieving HBeAg seroconversion or HBsAg loss.
• Liver cancer surveillance: Six-monthly ultrasound scans are recommended for patients at increased risk of hepatocellular carcinoma (those with cirrhosis, and certain non-cirrhotic patients based on age, ethnicity, and family history).
• Liver-protective lifestyle: Abstain from or minimise alcohol, maintain a healthy weight, eat a balanced diet, exercise regularly, and avoid hepatotoxic supplements or medications.

If HBsAg Negative and Not Immune

• Get vaccinated: The hepatitis B vaccine is highly effective (95% protection) and is available on the NHS for at-risk groups. Since 2017, it is part of the routine UK childhood immunisation schedule.

When Should You Get Tested?

HBsAg testing is recommended in the following situations:

• You are pregnant (routine NHS antenatal screening)
• You have symptoms of hepatitis (jaundice, dark urine, pale stools, fatigue, abdominal pain)
• You have elevated liver enzymes (ALT, AST) without a clear cause
• You were born in a country with intermediate or high hepatitis B prevalence
• You are a household or sexual contact of someone with hepatitis B
• You are a man who has sex with men
• You have ever injected drugs
• You are HIV positive (co-infection is common and alters management)
• You are about to start immunosuppressive therapy
• You are a healthcare worker in an exposure-prone role
• You are donating blood, organs, or tissue

NICE recommends a proactive approach to hepatitis B testing, particularly in primary care settings serving populations with higher prevalence. Early diagnosis significantly improves outcomes and prevents onward transmission.

Which Lola Health Tests Include Hepatitis B Surface Antigen?

Lola Health offers full blood testing to help you understand your liver health and infection status:

• Peak Insights - Our most detailed health assessment, covering liver function and a wide range of biomarkers for a complete health picture.
• Vital Check — A thorough wellness panel including key liver markers to monitor your health and identify potential concerns early.
• Core Health — An essential health check covering foundational biomarkers including liver function for a clear view of your overall wellbeing.

All Lola Health tests use venous blood draws performed by qualified phlebotomists, ensuring medical-grade accuracy. Results are reviewed by GP-certified professionals and come with personalised health recommendations.